exRNAdisease

Entry Detail

---



General Information

Database ID: exR0356615 RNA Name: hsa-miR-24-3p RNA Type: miRNA Chromosome: chr9 Starnd: + Coordinate: Start Site(bp): 95086064 End Site(bp): 95086085 External Links: hsa-miR-24-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AEN chr15 88621337 88632281 + AMOTL2 chr3 134355874 134375479 - APPL2 chr12 105173297 105236203 - ARPP19 chr15 52547045 52569883 - CD74 chr5 150400041 150412929 - CEP170B chr14 104865268 104896770 + CGN chr1 151510510 151538692 + CPA4 chr7 130293134 130324180 + CREG1 chr1 167529117 167553805 - CYB5B chr16 69424619 69466264 + DNAJB6 chr7 157335381 157417439 + GALNT10 chr5 154190730 154420984 + GIGYF1 chr7 100679507 100694037 - PLEKHM1 chr17 45435900 45490749 - RUBCN chr3 197668867 197749727 - STK4 chr20 44966479 45080021 + TMEM9 chr1 201134772 201171574 - WDR36 chr5 111091716 111130502 + GSK3B chr3 119821323 120094417 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000402 chr12 53670403 53671011 + hsa_circ_0000155 chr1 168007608 168014465 + hsa_circ_0000733 chr17 1561546 1562030 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand A1BG-AS1 chr19 58347718 58355455 + AC005034.3 chr2 75697583 75697996 + AC005394.2 chr19 28435388 28727680 - AC027031.2 chr8 106270144 106272902 + AC079781.5 chr7 97851688 97972985 - AC091564.7 chr11 6610883 6616594 - AL031282.2 chr1 1702736 1737688 - DIO3OS chr14 101552221 101560431 - EBLN3P chr9 37079645 37090928 + KCNQ1OT1 chr11 2608328 2699994 - MCM3AP-AS1 chr21 46229196 46259390 + MIR22HG chr17 1711493 1717174 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.